Evaxion Biotech A/S’s (EVAX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a research note published on Thursday,Benzinga reports. HC Wainwright currently has a $14.00 target price on the stock.

Separately, Lake Street Capital reduced their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th.

Evaxion Biotech A/S Stock Performance

EVAX opened at $2.53 on Thursday. Evaxion Biotech A/S has a 12-month low of $2.22 and a 12-month high of $22.05. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. The firm has a market capitalization of $2.96 million, a PE ratio of -1.74 and a beta of -0.28. The firm has a 50 day moving average of $3.65 and a two-hundred day moving average of $9.57.

Hedge Funds Weigh In On Evaxion Biotech A/S

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Invst LLC grew its position in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 16.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,400 shares of the company’s stock after purchasing an additional 7,200 shares during the quarter. Invst LLC owned approximately 4.31% of Evaxion Biotech A/S worth $43,000 as of its most recent SEC filing. 11.04% of the stock is owned by hedge funds and other institutional investors.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.